UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): February 18, 2020


                               CEL-SCI CORPORATION
                             ----------------------
             (Exact name of registrant as specified in its charter)


       Colorado                     001-11889               84-0916344
----------------------------    -------------------    ----------------------
(State or other jurisdiction   (Commission File No.)       (IRS Employer
      of incorporation)                                 Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)


      Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                  --------------------------------------------
          (Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-14c))

Securities registered pursuant to Section 12(b) of the Act:

                                                 Name of Each Exchange
     Title of Each Class   Trading Symbol(s)      on Which Registered
     -------------------   -----------------     --------------------
     Common Stock               CVM                  NYSE American

Indicate by check mark whether the  registrant is an emerging  growth company as
defined in Rule 405 of the Securities  Act of 1933  (ss.203.405 of this chapter)
or Rule  12b-2 of the  Securities  Exchange  Act of 1934  (ss.204.12b-2  of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]

                                       1
<PAGE>

Item 5.03   Amendments to Articles of Incorporation or Bylaws, Change in Fiscal
            Year End.

     On  February  18,  2020,  CEL-SCI's  directors  amended  Article  X of  the
Company's bylaws. The amended Article X reads as follows:

                                    ARTICLE X
                               SHAREHOLDER CLAIMS

     In the event that any shareholder  initiates or asserts a claim against the
Corporation,  or any  officer or  director  of the  Corporation,  including  any
derivative claim or claim  purportedly  filed on behalf of the Corporation,  and
the  shareholder  does not obtain a judgment  on the merits  that  substantially
achieves, in substance and amount, the full remedy sought, then such shareholder
shall be obligated  (jointly and  severally in the event the claim us brought by
more than one  shareholder)  to  reimburse  the  Corporation  and any officer or
director of the Corporation  for all fees,  costs and expenses of every kind and
description  (including,  but not limited to, all reasonable attorney's fees and
other litigation expenses) that the Corporation or its officers or directors may
incur  in  connection  with  such  claim.  Any  shareholder  claim  against  the
Corporation,  or any  officer or  director  of the  Corporation,  including  any
derivative claim or claim purportedly  filed on behalf of the Corporation,  must
be brought in the U.S. District Court for the district of Delaware.









                                       2
<PAGE>



                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  February 19, 2020                CEL-SCI CORPORATION



                                        By: /s/ Geert R. Kersten
                                            ------------------------------------
                                            Geert R. Kersten
                                            Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8k503amdbylaws2-20.txt", "secsgml_size_bytes": 4993}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "20633513"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): February 18, 2020

                               CEL-SCI CORPORATION
                             ----------------------
             (Exact name of registrant as specified in its charter)

       Colorado                     001-11889               84-0916344
----------------------------    -------------------    ----------------------
(State or other jurisdiction   (Commission File No.)       (IRS Employer
      of incorporation)                                 Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)

      Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                  --------------------------------------------
          (Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-14c))

Securities registered pursuant to Section 12(b) of the Act:

                                                 Name of Each Exchange
     Title of Each Class   Trading Symbol(s)      on Which Registered
     -------------------   -----------------     --------------------
     Common Stock               CVM                  NYSE American

Indicate by check mark whether the  registrant is an emerging  growth company as
defined in Rule 405 of the Securities  Act of 1933  (ss.203.405 of this chapter)
or Rule  12b-2 of the  Securities  Exchange  Act of 1934  (ss.204.12b-2  of this
chapter.

Emerging growth company [ ]

If an emerging  growth  company,  indicate by check mark if the  registrant  has
elected not to use the extended  transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]

                                       1
Item 5.03   Amendments to Articles of Incorporation or Bylaws, Change in Fiscal
            Year End.

     On  February  18,  2020,  CEL-SCI's  directors  amended  Article  X of  the
Company's bylaws. The amended Article X reads as follows:

                                    ARTICLE X
                               SHAREHOLDER CLAIMS

     In the event that any shareholder  initiates or asserts a claim against the
Corporation,  or any  officer or  director  of the  Corporation,  including  any
derivative claim or claim  purportedly  filed on behalf of the Corporation,  and
the  shareholder  does not obtain a judgment  on the merits  that  substantially
achieves, in substance and amount, the full remedy sought, then such shareholder
shall be obligated  (jointly and  severally in the event the claim us brought by
more than one  shareholder)  to  reimburse  the  Corporation  and any officer or
director of the Corporation  for all fees,  costs and expenses of every kind and
description  (including,  but not limited to, all reasonable attorney's fees and
other litigation expenses) that the Corporation or its officers or directors may
incur  in  connection  with  such  claim.  Any  shareholder  claim  against  the
Corporation,  or any  officer or  director  of the  Corporation,  including  any
derivative claim or claim purportedly  filed on behalf of the Corporation,  must
be brought in the U.S. District Court for the district of Delaware.

                                       2
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  February 19, 2020                CEL-SCI CORPORATION

                                        By: /s/ Geert R. Kersten
                                            ------------------------------------
                                            Geert R. Kersten
                                            Chief Executive Officer